Report Details:
15 Companies Covered
200 Pages
Nuclear Medicine Market Valuation To Reach USD 34.69 billion by 2035
Growing Incidence of Cancer and Technological Advancements will Positively Impact the Global Nuclear Medicine Market at a CAGR of 11.35% during the Forecast Period 2025 to 2035.
Market Research Future (MRFR) has published a cooked research report on the “Global Nuclear Medicine Market” that contains information from 2019 to 2035. The Nuclear Medicine Market is estimated to register a CAGR of 11.35% during the forecast period of 2025 to 2035, reaching USD 34.69 billion by 2035 from USD 10.63 billion in 2024.
MRFR recognizes the following companies as the key players in the Global Nuclear Medicine Market — GE Healthcare (US), Siemens Healthineers (DE), Philips Healthcare (NL), Canon Medical Systems (JP), Elekta (SE), Bayer AG (DE), Bracco Imaging (IT), Lantheus Medical Imaging (US), and NorthStar Medical Radioisotopes (US).
Market Highlights
The Global Nuclear Medicine Market is projected to witness significant growth, primarily driven by technological advancements, increasing incidence of cancer, and growing adoption of personalized medicine. The industry is undergoing a transformative phase with rapid progress in radiopharmaceutical development and hybrid imaging systems that enhance both diagnostic accuracy and therapeutic efficacy.
The increasing prevalence of chronic diseases, including cardiovascular disorders and cancer, is fueling demand for precise diagnostic and therapeutic solutions. Moreover, the integration of AI-based imaging tools, combined with rising awareness of nuclear medicine applications, is creating new growth opportunities across both developed and emerging markets.
The North American region leads the global market, backed by advanced healthcare infrastructure and high adoption of nuclear imaging technologies. Meanwhile, the Asia-Pacific region is anticipated to record the fastest growth during the forecast period due to rising healthcare investments, expanding patient base, and government support for advanced diagnostic techniques.
Segment Analysis
The Global Nuclear Medicine Market has been segmented based on Application, Radioisotope Type, End User, Procedure, and Region.
Based on Application, the market is segmented into Diagnostic Imaging, Therapeutic Applications, Radiopharmaceutical Production and Research Applications. The Diagnostic Imaging segment dominated the market in 2024, driven by the rising use of Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) for disease detection and monitoring. However, Therapeutic Applications are expected to grow at the highest rate due to advancements in targeted radionuclide therapies and personalized cancer treatment.
By Radioisotope Type, the segment includes Technetium-99m, Iodine-131, Fluorine-18 and Yttrium-90. Technetium-99m held the largest share in 2024, owing to its versatility in diagnostic procedures and optimal half-life. On the other hand, Fluorine-18 is projected to be the fastest-growing isotope segment due to its expanding use in PET imaging and oncology diagnostics.
By End User, the segment includes Hospitals, Diagnostic Imaging Centers, Academic Research Institutions and Pharmaceutical Companies. Hospitals accounted for the largest market share in 2024, supported by the integration of advanced nuclear medicine technologies within multidisciplinary care systems. Meanwhile, Diagnostic Imaging Centers are expected to grow rapidly as they focus on specialized imaging services and faster patient turnaround.
Based on Procedure, the market is segmented into Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Radiotherapy and Brachytherapy. Positron Emission Tomography (PET) remains the dominant procedure in the market, offering superior imaging for oncology, neurology, and cardiology. Single-Photon Emission Computed Tomography (SPECT), however, is anticipated to grow at the fastest pace due to technological advancements and its cost-effectiveness.
Regional Analysis
The Global Nuclear Medicine Market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America dominates the market with approximately 45% share, driven by strong healthcare infrastructure, continuous innovation, and presence of leading players such as GE Healthcare and Lantheus Medical Imaging. Supportive regulatory frameworks and high patient awareness further enhance market penetration.
Europe holds around 30% of the global share, supported by strict regulatory standards and a strong focus on safety and efficacy. Germany and the UK lead the region’s growth, backed by active R&D and technological innovations from key companies such as Siemens Healthineers and Bayer AG.
Asia-Pacific is the fastest-growing region, accounting for nearly 20% of the global market in 2024. Growth is fueled by rising healthcare spending, a growing aging population, and rapid adoption of advanced imaging systems, particularly in China, Japan, and India.
Middle East and Africa hold a smaller yet expanding share, with increasing healthcare investments and government initiatives to enhance diagnostic infrastructure, particularly in the UAE and South Africa.
Key Findings of the Study
- The Global Nuclear Medicine Market is expected to reach USD 34.69 billion by 2035, at a CAGR of 11.35% during 2025–2035.
- North America accounted for the largest market share, while Asia-Pacific is the fastest-growing region.
- Diagnostic Imaging dominated by Technetium-99m-based applications remains the largest segment.
- Therapeutic Applications driven by Fluorine-18 and Yttrium-90 isotopes are witnessing rapid growth.
- Leading players such as GE Healthcare, Siemens Healthineers, Bayer AG, and Lantheus Medical Imaging are driving market innovation through R&D, AI integration, and product diversification.
